What is the optimal duration of bisphosphonate therapy?

Cleve Clin J Med. 2011 Sep;78(9):619-30. doi: 10.3949/ccjm.78a.11022.

Abstract

It is reasonable to stop bisphosphonates after 5 years of use and then to follow patients with markers of bone turnover. As long as the levels of these markers remain reduced, adding an antiresorptive drug does not make physiologic sense.

Publication types

  • Review

MeSH terms

  • Alendronate / therapeutic use
  • Biomarkers
  • Bone Density Conservation Agents / adverse effects
  • Bone Density Conservation Agents / therapeutic use*
  • Diphosphonates / adverse effects
  • Diphosphonates / therapeutic use*
  • Etidronic Acid / analogs & derivatives
  • Etidronic Acid / therapeutic use
  • Femoral Fractures / etiology
  • Femoral Fractures / prevention & control
  • Fractures, Bone / etiology
  • Fractures, Bone / prevention & control*
  • Humans
  • Osteoporosis / complications
  • Osteoporosis / drug therapy*
  • Osteoporosis / metabolism
  • Risedronic Acid
  • Risk Factors
  • Time Factors

Substances

  • Biomarkers
  • Bone Density Conservation Agents
  • Diphosphonates
  • Risedronic Acid
  • Etidronic Acid
  • Alendronate